Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2/3 1

Status

Withdrawn 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Melanoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Trastuzumab 209Paclitaxel 187Fulvestrant 161Capecitabine 150Docetaxel 136Letrozole 127exemestane 92palbociclib 76Anastrozole 75Cyclophosphamide 71Lapatinib 69Gemcitabine 66Bevacizumab 66pertuzumab 61pembrolizumab 60ribociclib 59Carboplatin 59abemaciclib 53eribulin 48Doxorubicin 45Vinorelbine 41Everolimus 41Ado-Trastuzumab Emtansine 41Tamoxifen 40130-nm albumin-bound paclitaxel 34Injections 31trastuzumab deruxtecan 30Albumin-Bound Paclitaxel 26olaparib 24Alpelisib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Breast Neoplasms × soluble LAG-3 protein, human × Clear all
NCT05747794 2024-12-17

AIPAC-003

Immutep S.A.S.

Phase 2/3 Active not recruiting
849 enrolled
Breast

Breast Neoplasms

NCT04252768 2023-03-22

AIPAC-002

Immutep S.A.S.

Phase 1 Withdrawn
Breast

Breast Neoplasms

NCT00349934 2010-01-07

IMP321 Plus First-line Paclitaxel in Metastatic Breast Carcinoma

Immutep S.A.S.

Phase 1 Completed
33 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡